| 1.51 0.21 (16.15%) | 07-30 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.95 | 1-year : | 2.27 |
| Resists | First : | 1.67 | Second : | 1.95 |
| Pivot price | 1.5  |
|||
| Supports | First : | 1.22 | Second : | 1.01 |
| MAs | MA(5) : | 1.51 |
MA(20) : | 1.53 |
| MA(100) : | 1.12 |
MA(250) : | 1.81 |
|
| MACD | MACD : | -0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 49.9 |
D(3) : | 59.6 |
| RSI | RSI(14): 48.4 |
|||
| 52-week | High : | 10 | Low : | 0.55 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ GNTA ] has closed below upper band by 49.9%. Bollinger Bands are 8.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1.53 - 1.54 | 1.54 - 1.54 |
| Low: | 1.39 - 1.4 | 1.4 - 1.41 |
| Close: | 1.49 - 1.51 | 1.51 - 1.52 |
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.
Thu, 30 Jul 2026
Genenta Science SPA (GNTA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Wed, 29 Jul 2026
GNTA|Genenta Science SPA|Price:1.360|Chg%:-0.210 - TradingKey
Mon, 27 Jul 2026
Genenta Science SPA (GNTA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Thu, 23 Jul 2026
Robot Tackles Maintenance Inside a Fusion Machine at 20M°C - Stock Titan
Tue, 14 Jul 2026
Court restores Genenta Science (GNTA) corporate purpose amendment - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 48 (M) |
| Shares Float | 14 (M) |
| Held by Insiders | 42.4 (%) |
| Held by Institutions | 7.1 (%) |
| Shares Short | 146 (K) |
| Shares Short P.Month | 192 (K) |
| EPS | -0.38 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.05 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -17.7 % |
| Return on Equity (ttm) | -38.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.14 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -3 (M) |
| PE Ratio | -3.98 |
| PEG Ratio | 0 |
| Price to Book value | 1.42 |
| Price to Sales | 0 |
| Price to Cash Flow | -10.6 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|